FeesSafety
Pluang+

Quarterhill posts Q3 revenue growth, margin expansion, and repays convertible debentures, strengthening its financial position.

Company Fundamentals
10 Nov 2026, 14:00 WIB
PRNewsWire
View Source
Bullish
Quarterhill posts Q3 revenue growth, margin expansion, and repays convertible debentures, strengthening its financial position.

Quarterhill reported a 9% year-over-year revenue increase to $43.2 million in Q3 2026, its highest since 2022, alongside a gross margin expansion to 29%. The company achieved its fifth consecutive quarter of positive Adjusted EBITDA at $3.9 million and fully repaid its CAD$57.5 million convertible debentures, improving its balance sheet. Key contract wins and ongoing efforts to close the Conduent tolling acquisition position Quarterhill for future growth and operational strength.

Quarterhill's Q3 2026 financial results provide context for readers. For those following the Technology sector, here is Pluang's market snapshot as of Nov 10, 2026 18:12 WIB: out of 150 priced US tech stocks, 51 advanced while 89 declined. Kaltura Inc (KLTR) surged 15.38% to USD 1.65 with a typical hold time of 22 days, contrasting with Grab Holdings Ltd. (GRAB) which dropped 6.10% to USD 3.23 and saw 99% sell orders over a 96-day hold. ASE Technology Holding Co Ltd (ASX) rose 6.02% to USD 36.43, with a more balanced order activity of 57% buy and 43% sell over 50 days.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
56 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
56 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
56 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
56 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App